Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
The House-passed OBBB revives 100% bonus depreciation and introduces new deductions for qualified production property and manufacturing.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Wyoming House Bill 11 expands the manufacturing sales and use tax exemptions. We break down what this means for businesses operating in Wyoming.
Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.
Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.
Explore the top five impacts tariffs may have on your business taxes and learn steps and key strategies to manage costs, credits and compliance.
The National Association of Manufacturers (NAM) has released its Q4 Manufacturers’ Survey. Learn more about what it means for leadership in 2025.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.
With 2024 coming to a close, time is running out for manufacturing companies to take advantage of many year-end tax benefits.
The National Association of Manufacturers (NAM) conducted its Q3 Outlook Survey. Read more for a discussion and analysis of the results.
CEOs can leverage established ESG principles and best practices to create sustainable business operations and promote long-term growth.
